2010 Hema intro

Article

Visit ONCOLOGY’s on-site coverage of the annual meeting: Internationally regarded oncologists gave exclusive interviews and expert perspective reports on the highlights of this year’s meeting. See the links below for  Hematologic Cancers session coverage from hematologic malignancy authority Samuel M. Silver, MD, PhD, University of Michigan

Visit ONCOLOGY’s on-site coverage of the annual meeting: Internationally regarded oncologists gave exclusive interviews and expert perspective reports on the highlights of this year’s meeting. See the links below for  Hematologic Cancers session coverage from hematologic malignancy authority Samuel M. Silver, MD, PhD, University of Michigan

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Related Content
Novel Microbiome-Based Therapy Safe, Tolerable in GI-aGVHD

Novel Microbiome-Based Therapy Safe, Tolerable in GI-aGVHD

Andrea Eleazar, MHS
December 9th 2025
Article

The primary end point of GI overall response rate was met with MaaT013 for GI-aGVHD.

Why Sexual and Gender Minority Care is an Oncologic Imperative

Why Sexual and Gender Minority Care is an Oncologic Imperative

Daniel C. McFarland, DO;Charles S. Kamen, PhD, MPH
December 8th 2025
Podcast

Daniel C. McFarland, DO, and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.

Data from a phase 1/2 trial support sonrotoclax as a promising treatment option in previously treated relapsed/refractory mantle cell lymphoma.

Sonrotoclax Elicits Responses in Relapsed/Refractory Mantle Cell Lymphoma

Kyle Doherty
December 8th 2025
Article

Data from a phase 1/2 trial support sonrotoclax as a promising treatment option in previously treated relapsed/refractory mantle cell lymphoma.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

MARIPOSA Final OS Results in Asia Population Yield Meaningful Improvement in EGFR NSCLC

MARIPOSA Final OS Results in Asia Population Yield Meaningful Improvement in EGFR NSCLC

Ariana Pelosci
December 8th 2025
Article

In the amivantamab/lazertinib arm, the median OS in the Asian population was not reached vs 38.4 months in the osimertinib arm for patients with EGFR-mutated NSCLC.

Among patients with NPM1-mutated and KMT2A-rearranged disease, respectively, the ORR was 65% and 41% in the phase 1 KOMET-007 trial.

Ziftomenib Combo Exhibits Tolerability/Early Activity in NPM1/KMT2A+ AML

Roman Fabbricatore
December 8th 2025
Article

Among patients with NPM1-mutated and KMT2A-rearranged disease, respectively, the ORR was 65% and 41% in the phase 1 KOMET-007 trial.